年龄、血管健康与老年人群阿尔茨海默病生物标志物
基于Mayo Clinic老化研究人群中430名60岁以上认知连续谱个体,评估年龄、血管健康与AD影像生物标志物的关联。结果显示血管健康对神经退行性变的直接影响大于对淀粉样蛋白沉积的影响,且高脂血症与内嗅皮层tau摄取直接相关。
要点
- 血管健康对AD特征区神经退行性变的影响可量化地大于对淀粉样蛋白沉积的影响。
- 存在心血管代谢疾病者神经退行性变显著高于无此类疾病者,但淀粉样蛋白和内嗅皮层tau无组间差异。
- 高脂血症与内嗅皮层tau摄取存在显著直接关联。
核心结论
- 血管健康对AD特征区神经退行性变的影响可量化地大于对淀粉样蛋白沉积的影响。
- 血管健康对神经退行性变有显著直接和间接影响,但对淀粉样蛋白无显著影响。
- 血管健康(特别是高脂血症的存在)对内嗅皮层tau摄取有显著直接影响。
研究设计与样本
- 基于人群的Mayo Clinic老化研究,纳入430名年龄>60岁、处于认知连续谱的个体,均接受淀粉样蛋白PET、tau PET和MRI扫描。
- 其中329名个体有FDG PET。
- 从医疗记录中确定现患心血管和代谢疾病(CMC),以高血压、高脂血症、心律失常、冠心病、充血性心力衰竭、糖尿病和卒中的有无之和作为血管健康的替代指标。
主要发现
- CMC+参与者神经退行性变显著大于CMC-参与者,但淀粉样蛋白和内嗅皮层tau无显著组间差异。
- 结构方程模型显示血管健康对神经退行性变有显著直接和间接影响,但对淀粉样蛋白无显著影响。
- 血管健康(特别是高脂血症的存在)对内嗅皮层tau摄取有显著直接影响。
关键数值与推荐
- 以全局淀粉样蛋白(Pittsburgh compound B PET)、内嗅皮层tau摄取(tau PET)以及AD特征区神经退行性变(MRI和FDG-PET)作为AD病理生理的替代指标。
- 将参与者二分为CMC=0(CMC-)与CMC>0(CMC+),检验年龄校正后的组间AD生物标志物差异。
- 采用结构方程模型评估血管健康对AD生物标志物级联(淀粉样蛋白导致tau导致神经退行性变)的影响,并考虑年龄、性别和载脂蛋白E的直接和间接效应。
临床怎么用
- 在老年人群中评估AD风险时,应关注血管健康对神经退行性变的独立影响。
- 高脂血症可能与内嗅皮层tau沉积相关,提示血管风险管理或影响tau病理。
局限性
- 横断面设计无法明确tau沉积与血管健康之间的因果关系,需纵向研究进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the associations between age, vascular health, and Alzheimer disease (AD) imaging biomarkers in an elderly sample. METHODS: We identified 430 individuals along the cognitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magnetic resonance imaging (MRI) scans from the population-based Mayo Clinic Study of Aging. A subset of 329 individuals had fluorodeoxyglucose (FDG) PET. We ascertained presently existing cardiovascular and metabolic conditions (CMC) from health care records and used the summation of presence/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke as a surrogate for vascular health. We used global amyloid from Pittsburgh compound B PET, entorhinal cortex tau uptake (ERC-tau) from tau-PET, and neurodegeneration in AD signature regions from MRI and FDG-PET as surrogates for AD pathophysiology. We dichotomized participants into CMC = 0 (CMC- ) versus CMC > 0 (CMC+ ) and tested for age-adjusted group differences in AD biomarkers. Using structural equation models (SEMs), we assessed the impact of vascular health on AD biomarker cascade (amyloid leads to tau leads to neurodegeneration) after considering the direct and indirect age, sex, and apolipoprotein E effects. RESULTS: CMC+ participants had significantly greater neurodegeneration than CMC- participants but did not differ by amyloid or ERC-tau. The SEMs showed that (1) vascular health had a significant direct and indirect impact on neurodegeneration but not on amyloid; and (2) vascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC-tau. INTERPRETATION: Vascular health had quantifiably greater impact on neurodegeneration in AD regions than on amyloid deposition. Longitudinal studies are warranted to clarify the relationship between tau deposition and vascular health. Ann Neurol 2017;82:706-718.
引用
- Vemuri P, Lesnick TG, Przybelski SA, et al. Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol. 2017. PMID: 29023983. doi:10.1002/ana.25071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。